<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437397</url>
  </required_header>
  <id_info>
    <org_study_id>LAC-MD-31</org_study_id>
    <nct_id>NCT01437397</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase III study is to assess the maintenance bronchodilator effects of
      the fixed dose combination versus monotherapies. This study will also assess the effects of
      the fixed dose combination in terms of COPD symptoms, disease related health status and the
      long-term safety and tolerability of the fixed dose combination. This study will include a 24
      week treatment period, preceding by a run-in period, followed by a two week follow up visit.
      All patients will be randomized to one of four treatment arms or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Week 24 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Morning Trough Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Week 24 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Transition Dyspnea Index (TDI) Focal Score</measure>
    <time_frame>Week 24 of treatment</time_frame>
    <description>The TDI measures the change from baseline in severity of breathlessness in symptomatic patients. The TDI contains a rating for 3 categories (functional impairment, magnitude of task, magnitude of effort).TDI scale ranges from -3 (major deterioration) to +3 (major improvement) including a 0 score to indicate &quot;no change&quot;. The 3 categories are added to obtain a focal score ranging from -9 (including 0) to +9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Week 24 of treatment</time_frame>
    <description>St George's Respiratory Questionnaire (SGRQ) measures COPD-specific health outcomes and consists of 2 parts with 3 dimension scores (a symptom score and an activity and impacts score). SGRQ total score is the sum of these scores and ranges from 0 (best health status) to 100 (worst health status).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1692</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aclidinium monotherapy 400 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol monotherapy 12 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium Bromide/Formoterol Fumarate</intervention_name>
    <description>Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium Bromide/Formoterol Fumarate</intervention_name>
    <description>Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium Bromide</intervention_name>
    <description>Inhaled Aclidinium 400 μg, twice per day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate</intervention_name>
    <description>Inhaled Formoterol 12 μg, twice per day</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled dose-matched placebo, twice per day</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients at least 40 years of age

          -  Current or former cigarette smoker with a cigarette smoking history of at least 10
             pack-years

          -  A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined
             by the GOLD guidelines and stable airway obstruction. Patients had to have a
             postbronchodilator FEV1/FVC ratio &lt; 70% at Visit 1 (GOLD, 2010)

          -  Post-albuterol/salbutamol FEV1 values ≥ 30% and &lt; 80% of predicted value. FEV1 was
             measured at the Screening Visit (Visit 1) 10 to 15 minutes after inhalation of
             albuterol/salbutamol. Predicted normal used for calculation purposes were based on
             National Health and Nutrition Examination Survey III predicted values (Hankinson et
             al, 1999)

          -  Able to perform acceptable and repeatable pulmonary function testing for FEV1
             according to ATS/ERS criteria (Miller et al, 2005) at Screening Visit (Visit 1) and
             throughout their participation in the trial

          -  Negative serum β-human chorionic gonadotropin pregnancy test at Visit 1 and must have
             been using hormonal contraceptives or a barrier method plus a spermicidal agent;
             otherwise at least 1-year postmenopausal or surgically sterile, defined as having a
             hysterectomy or tubal ligation (applied to female patients only)

          -  Judged by the Principal Investigator to be in otherwise good stable health based on
             medical history, physical examination, ECGs, and routine laboratory data evaluations

          -  Patients previously randomized in an aclidinium monotherapy trial were permitted as
             long as it had been at least 6 months since the completion of their previous trial
             participation

          -  Able to understand the study procedures and be willing to participate in the study as
             indicated by signing the informed consent

        Exclusion Criteria:

          -  Hospitalization for an acute COPD exacerbation within 3 months before Visit 1

          -  Any respiratory tract infection (including the upper respiratory tract) or COPD
             exacerbation in the 6 weeks before Visit 1. Patients who developed a respiratory tract
             infection or COPD exacerbation during the washout or run-in period were discontinued
             from the study before randomization

          -  Any clinically significant respiratory conditions other than COPD, including active
             tuberculosis, history of interstitial lung disease, pulmonary thromboembolic disease,
             history of α1-antitrypsin deficiency, pulmonary resection, lung volume surgery, or any
             other thoracic surgery during the past 12 months, history of bronchiectasis secondary
             to respiratory diseases other than COPD (eg, cystic fibrosis, Kartagener syndrome),
             post organ transplantation, or expected to require thoracotomy or other lung surgery
             during the study

          -  Clinical history suggesting that the patient had asthma as opposed to COPD (Study
             Physician was to be contacted to discuss eligibility, if necessary)

          -  Chronic use of oxygen therapy ≥ 15 hours/day

          -  Body mass index(BMI) ≥ 40 kg/m2

          -  Patients who intended to start a pulmonary rehabilitation program during the trial
             were excluded, as well as those who finished or started it within 3 months prior to
             Screening Visit

          -  Clinically significant cardiovascular conditions including: myocardial infarction
             within the previous 6 months; newly diagnosed arrhythmia within the previous 3 months;
             unstable angina; unstable arrhythmia that had required changes in pharmacological
             therapy or other intervention within the previous 6 months; the presence of an
             automated implantable cardioverter-defibrillator; history of thoracic surgery within
             the past year before screening; hospitalization within the previous 12 months for
             heart failure of New York Heart Association functional class III (marked limitation of
             physical activity and only comfortable at rest, less than ordinary activity causes
             fatigue, palpitation or dyspnea), or class IV (unable to carry out any physical
             activity without discomfort) (Criteria Committee of the New York Heart Association
             criteria, 1994)

          -  Any uncontrolled infection that may have placed the patient at risk resulting from
             human immunodeficiency virus, active hepatitis and/or patients with diagnosed active
             tuberculosis

          -  QTcB &gt; 470 msec in the resting ECGs performed at Screening (Visit 1), as indicated in
             the centralized ECG vendor generated report. Patients who were on a stable dose of
             medication that may prolong the QTc, but had a documented, stable, and normal QTc,
             could have been considered

          -  QTcB &gt; 470 msec in the resting ECGs performed before randomization at Visit 2, as
             indicated in the paper tracing generated by the Sponsor-provided ECG equipment

          -  Clinically relevant abnormalities in the results of the clinical laboratory tests, in
             ECG parameters other than QTc, or in the physical examination or vital signs at Visit
             1 except for those related to COPD

          -  History of drug or alcohol abuse within the previous 5 years

          -  Any other serious or uncontrolled physical or mental condition/disease that, as judged
             by the Investigator, could have placed the patient at higher risk derived from his/her
             participation in the study, could have confounded the results of the study, or would
             be likely to have prevented the patient from complying with the requirements of the
             study or completing the study. If there was a history of such disease, but the
             condition had been stable for more than 1 year and was judged by the Investigator not
             to interfere with the patient's participation in the study, the patient may have been
             included, with the documented approval of the Study Physician

          -  History of hypersensitivity reaction to inhaled anticholinergics, beta-2 agonists,
             sympathomimetic amines, or inhaled medication or any component thereof (including
             report of paradoxical bronchospasm) or a history of acute urinary retention,
             symptomatic benign prostatic hyperplasia, bladder neck obstruction, or narrow-angle
             glaucoma. (Note: Patients who had well controlled, stable, asymptomatic benign
             prostatic hyperplasia were not to be excluded)

          -  Sitting, resting systolic BP ≥ 160 mm Hg and/or diastolic BP ≥ 100 mm Hg at Visit 1
             and Visit 2

          -  Unable to use a multidose dry-powder inhaler or a pressurized metered-dose inhaler

          -  Treatment with any other investigational product within 30 days (or 6 half-lives,
             whichever was longer) before Visit 1

          -  Previous participation in a clinical trial with aclidinium bromide in an FDC therapy

          -  Pregnant or breastfeeding

          -  Current diagnosis of cancer (present in the patient) other than basal or squamous cell
             skin cancer. Patients who had a history of cancer must have been cleared before Visit
             1 (Screening) on a case-by-case basis

          -  Patients who did not maintain regular day/night, waking/sleeping cycles (eg, night
             shift workers)

          -  Patients who intended to use any concomitant medication not permitted by this protocol
             or who had not undergone the required washout period for a particular prohibited
             medication (Appendix III of the protocol, which can be found in Appendix 16.1.1 of
             this report)

          -  Patients who were unlikely to be compliant with study requirements (eg, take their
             medication, complete their electronic diaries, attend clinic at the required times)

          -  Patients who were employees or relatives of employees of the investigative study
             center, FRI, Almirall, SA, or Pharmaceutical Product Development (PPD, Inc.)

          -  Patients who had any other conditions that, in the Investigator's opinion, might have
             indicated the patient to be unsuitable for the study or supported excluding the
             patient from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forest Investigative Site 1827</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1920</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <zip>35611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1162</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1493</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1937</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1893</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1824</name>
      <address>
        <city>Gulf Shores</city>
        <state>Alabama</state>
        <zip>36542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2088</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1918</name>
      <address>
        <city>Scottsboro</city>
        <state>Alabama</state>
        <zip>35768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0909</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1958</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1379</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1822</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1483</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1809</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1156</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1871</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1873</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2064</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1427</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1866</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95842</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1125</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1898</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2009</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1374</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1813</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1883</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1380</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1137</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1327</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1976</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1821</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1154</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1944</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1364</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1152</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1875</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0670</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1516</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0990</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1513</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1854</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1882</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1543</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1416</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1167</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1868</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1432</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1979</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1819</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1808</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1950</name>
      <address>
        <city>Oldsmar</city>
        <state>Florida</state>
        <zip>34677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1145</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1094</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1803</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 974</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1876</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1817</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1829</name>
      <address>
        <city>St. Cloud</city>
        <state>Florida</state>
        <zip>34769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1874</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2082</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2053</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2047</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1185</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1860</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1982</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1900</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0987</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1828</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1830</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2089</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0679</name>
      <address>
        <city>Coeur d' Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1858</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1095</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1912</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2051</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2033</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2085</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0539</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1478</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1519</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1811</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1430</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1812</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1814</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1924</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1865</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <zip>20636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1872</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1570</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1852</name>
      <address>
        <city>Fall river</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1029</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1431</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1892</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1342</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1487</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1128</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1527</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2041</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1124</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1619</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1118</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1884</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1587</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1602</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1856</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1867</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2079</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1399</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1599</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1831</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1400</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1609</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1948</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1815</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1363</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1907</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1911</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1908</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1804</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1807</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1834</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1562</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1559</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1923</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1949</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1151</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1489</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <zip>10538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0550</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1425</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2098</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1392</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2035</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1366</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1153</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1823</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1891</name>
      <address>
        <city>Cadiz</city>
        <state>Ohio</state>
        <zip>43907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1134</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1885</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1806</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2028</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1903</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1361</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1433</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2090</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1530</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1393</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1915</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1889</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2043</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1833</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1855</name>
      <address>
        <city>Clairton</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1820</name>
      <address>
        <city>Downington</city>
        <state>Pennsylvania</state>
        <zip>19335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1423</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1899</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1443</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1863</name>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <zip>19460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1146</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1449</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <zip>16684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1862</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1832</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1089</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2072</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1905</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1802</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1914</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1913</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1121</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1957</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1526</name>
      <address>
        <city>Fayetteville</city>
        <state>Tennessee</state>
        <zip>37334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1440</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1879</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1861</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1816</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1890</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1332</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2012</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1951</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1902</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1091</name>
      <address>
        <city>Mckinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1826</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0526</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1895</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1936</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1330</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>25403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1945</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1404</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1120</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1977</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1878</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1573</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0988</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1870</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1555</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1991</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1987</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1973</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1981</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1990</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2251</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2250</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1972</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1986</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1985</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2253</name>
      <address>
        <city>Adelaide</city>
        <state>Western Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1904</name>
      <address>
        <city>Langley</city>
        <state>British Columbia</state>
        <zip>V3A 4H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0905</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0976</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1877</name>
      <address>
        <city>Sarina</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1896</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1171</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2203</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1952</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2R 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0943</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1859</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1027</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1970</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1967</name>
      <address>
        <city>Dunedin</city>
        <zip>9012</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1964</name>
      <address>
        <city>Dunedin</city>
        <zip>9058</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1968</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1965</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1980</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1025</name>
      <address>
        <city>Wellington</city>
        <zip>7366</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4060&amp;filename=CSRsynopsis_redacted.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <results_first_submitted>November 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2017</results_first_posted>
  <disposition_first_submitted>April 5, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 5, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 11, 2013</disposition_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Airflow Obstruction, Chronic</keyword>
  <keyword>Chronic Airflow Obstruction</keyword>
  <keyword>Chronic Obstructive Airway Disease</keyword>
  <keyword>Chronic Obstructive Lung Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 205 sites, 178 in the United States, 9 in Canada, 10 in Australia, and 8 in New Zealand. The first patient was screened in October 2011 and the last patient visit was in February 2013</recruitment_details>
      <pre_assignment_details>A total of 3260 patients were screened for eligibility; 1692 patients were randomized to treatment. A total of 1568 (48.1%) patients screen failed and were discontinued prior to randomization. The primary reason for screening failures was not meeting inclusion/exclusion criteria (41.6%)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aclidinium/Formoterol 400/12 μg</title>
          <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
        </group>
        <group group_id="P2">
          <title>Aclidinium/Formoterol 400/6 μg</title>
          <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
        </group>
        <group group_id="P3">
          <title>Aclidinium 400 μg</title>
          <description>Administered BID by inhalation</description>
        </group>
        <group group_id="P4">
          <title>Formoterol 12 μg</title>
          <description>Administered BID by inhalation</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Administered BID by inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="338"/>
                <participants group_id="P3" count="340"/>
                <participants group_id="P4" count="339"/>
                <participants group_id="P5" count="337"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="276"/>
                <participants group_id="P3" count="268"/>
                <participants group_id="P4" count="270"/>
                <participants group_id="P5" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="101"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site termination/COPD exacerbation/other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population comprising all patients randomized to a treatment group who received at least 1 dose of double-blind investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Aclidinium/Formoterol 400/12 μg</title>
          <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
        </group>
        <group group_id="B2">
          <title>Aclidinium/Formoterol 400/6 μg</title>
          <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
        </group>
        <group group_id="B3">
          <title>Aclidinium 400 μg</title>
          <description>Administered BID by inhalation</description>
        </group>
        <group group_id="B4">
          <title>Formoterol 12 μg</title>
          <description>Administered BID by inhalation</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Administered BID by inhalation</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="335"/>
            <count group_id="B2" value="333"/>
            <count group_id="B3" value="337"/>
            <count group_id="B4" value="332"/>
            <count group_id="B5" value="332"/>
            <count group_id="B6" value="1669"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="8.9"/>
                    <measurement group_id="B2" value="63.9" spread="9.2"/>
                    <measurement group_id="B3" value="64.4" spread="8.7"/>
                    <measurement group_id="B4" value="63.7" spread="8.7"/>
                    <measurement group_id="B5" value="63.5" spread="8.9"/>
                    <measurement group_id="B6" value="63.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="157"/>
                    <measurement group_id="B6" value="782"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="169"/>
                    <measurement group_id="B5" value="175"/>
                    <measurement group_id="B6" value="887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Week 24 of treatment</time_frame>
        <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Administered BID by inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)</title>
          <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="333"/>
                <count group_id="O3" value="337"/>
                <count group_id="O4" value="332"/>
                <count group_id="O5" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.247" spread="0.013"/>
                    <measurement group_id="O2" value="0.226" spread="0.013"/>
                    <measurement group_id="O3" value="0.139" spread="0.013"/>
                    <measurement group_id="O4" value="0.165" spread="0.013"/>
                    <measurement group_id="O5" value="-0.037" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, sex, smoking-status, visit and group-by-visit as factors; screening pre- and post-bronchodilator FEV1, age and baseline FEV1 as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, sex, smoking-status, visit and group-by-visit as factors; screening pre- and post-bronchodilator FEV1, age and baseline FEV1 as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Trough Forced Expiratory Volume in One Second (FEV1)</title>
        <time_frame>Week 24 of treatment</time_frame>
        <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Administered BID by inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Trough Forced Expiratory Volume in One Second (FEV1)</title>
          <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="333"/>
                <count group_id="O3" value="337"/>
                <count group_id="O4" value="332"/>
                <count group_id="O5" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.012"/>
                    <measurement group_id="O2" value="0.076" spread="0.012"/>
                    <measurement group_id="O3" value="0.066" spread="0.012"/>
                    <measurement group_id="O4" value="0.050" spread="0.012"/>
                    <measurement group_id="O5" value="-0.035" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, sex, smoking-status, visit and group-by-visit as factors; screening pre- and post-bronchodilator FEV1, age and baseline FEV1 as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.079</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, sex, smoking-status, visit and group-by-visit as factors; screening pre- and post-bronchodilator FEV1, age and baseline FEV1 as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Transition Dyspnea Index (TDI) Focal Score</title>
        <description>The TDI measures the change from baseline in severity of breathlessness in symptomatic patients. The TDI contains a rating for 3 categories (functional impairment, magnitude of task, magnitude of effort).TDI scale ranges from -3 (major deterioration) to +3 (major improvement) including a 0 score to indicate &quot;no change&quot;. The 3 categories are added to obtain a focal score ranging from -9 (including 0) to +9.</description>
        <time_frame>Week 24 of treatment</time_frame>
        <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Administered BID by inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Transition Dyspnea Index (TDI) Focal Score</title>
          <description>The TDI measures the change from baseline in severity of breathlessness in symptomatic patients. The TDI contains a rating for 3 categories (functional impairment, magnitude of task, magnitude of effort).TDI scale ranges from -3 (major deterioration) to +3 (major improvement) including a 0 score to indicate &quot;no change&quot;. The 3 categories are added to obtain a focal score ranging from -9 (including 0) to +9.</description>
          <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="333"/>
                <count group_id="O3" value="337"/>
                <count group_id="O4" value="332"/>
                <count group_id="O5" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.017" spread="0.203"/>
                    <measurement group_id="O2" value="1.977" spread="0.199"/>
                    <measurement group_id="O3" value="1.558" spread="0.201"/>
                    <measurement group_id="O4" value="1.522" spread="0.201"/>
                    <measurement group_id="O5" value="0.582" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment group, sex, smoking-status, visit, and treatment group-by-visit as factors; visit, age baseline BDI/SGRQ as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>1.436</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.297</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.854</ci_lower_limit>
            <ci_upper_limit>2.018</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment group, sex, smoking-status, visit, and treatment group-by-visit as factors; visit, age baseline BDI/SGRQ as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>1.395</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.294</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.818</ci_lower_limit>
            <ci_upper_limit>1.972</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>St George’s Respiratory Questionnaire (SGRQ) measures COPD-specific health outcomes and consists of 2 parts with 3 dimension scores (a symptom score and an activity and impacts score). SGRQ total score is the sum of these scores and ranges from 0 (best health status) to 100 (worst health status).</description>
        <time_frame>Week 24 of treatment</time_frame>
        <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium/Formoterol 400/12 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium/Formoterol 400/6 μg</title>
            <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 400 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 12 μg</title>
            <description>Administered BID by inhalation</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Administered BID by inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>St George’s Respiratory Questionnaire (SGRQ) measures COPD-specific health outcomes and consists of 2 parts with 3 dimension scores (a symptom score and an activity and impacts score). SGRQ total score is the sum of these scores and ranges from 0 (best health status) to 100 (worst health status).</description>
          <population>ITT Population defined as all randomized patients who took at least one administration of study medication and had a baseline and at least one post-baseline FEV1 assessment</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="333"/>
                <count group_id="O3" value="337"/>
                <count group_id="O4" value="332"/>
                <count group_id="O5" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.568" spread="0.740"/>
                    <measurement group_id="O2" value="-5.942" spread="0.728"/>
                    <measurement group_id="O3" value="-6.438" spread="0.738"/>
                    <measurement group_id="O4" value="-4.701" spread="0.742"/>
                    <measurement group_id="O5" value="-2.215" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment group, sex, smoking-status, visit, and treatment group-by-visit as factors; visit, age baseline BDI/SGRQ as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-4.353</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.075</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.462</ci_lower_limit>
            <ci_upper_limit>-2.244</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment group, sex, smoking-status, visit, and treatment group-by-visit as factors; visit, age baseline BDI/SGRQ as covariates</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-3.728</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.819</ci_lower_limit>
            <ci_upper_limit>-1.637</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 26 ± 5 days</time_frame>
      <desc>Safety population comprised all patients randomized to a treatment group who received at least 1 dose of double-blind investigational treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aclidinium/Formoterol 400/12 μg</title>
          <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
        </group>
        <group group_id="E2">
          <title>Aclidinium/Formoterol 400/6 μg</title>
          <description>Fixed-dose combination (FDC) administered BID by inhalation</description>
        </group>
        <group group_id="E3">
          <title>Aclidinium 400 μg</title>
          <description>Administered BID by inhalation</description>
        </group>
        <group group_id="E4">
          <title>Formoterol 12 μg</title>
          <description>Administered BID by inhalation</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Administered BID by inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the hypopharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="333"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="332"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the results by the Investigator will be subject to mutual agreement between the investigator and sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical</name_or_title>
      <organization>Study Information Center</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

